US Patent US10555556B2 declared invalid in infringement case

Sep.21.2022
US Patent US10555556B2 declared invalid in infringement case
Philip Morris lost patent infringement case in the US and its patent was invalidated, impacting e-cigarette product development.

Recently, in Case No.1:20-cv-0039-LO-TCB, Phimosis International accused R.J. Reynolds of patent infringement with No.US10555556B2, but the patent has since been invalidated in the U.S. after a lengthy legal battle that ended in Phimosis International's defeat. What does this ruling mean for the development of domestic electronic cigarette products?


Author bio: Lawyer Tang Shunliang is a specialized attorney in the field of new tobacco at the Beijing Zhong Lun Wen De Kunming law firm.


Part 1: Case Review


In case number 1:20-cv-0039-LO-TCB, R.J. Reynolds has brought a lawsuit against Phimow International for copyright infringement. Phimow International has responded by countersuing R.J. Reynolds for a series of patent infringement cases, highlighting the intense nature of the patent litigation between these two parties.


The case identifier is 1:20-cv-0039-LO-TCB.


On June 15, 2022, the Eastern District Court of Virginia ruled that R.J. Reynolds had infringed on two electronic cigarette technology patents owned by Philip Morris, identified as No. US9814265 and No. US10104911. As a result, they were ordered to pay $10.76 million in damages.


In this case, Phemo International has presented several weapons in its charge of infringement, including the patent No. US10555556B2, and has provided extensive evidence and reasoning to accuse VUSE VIBE of continuous infringement since June 29, 2022, specifically violating the first right claim of the patent. If this charge is proven, the compensation amount will not be limited to 10.76 million.


The R.J. Reynolds company has responded by stating that the patent should not have been granted. This is why there is now news of the recent invalidation of the patent.


Phimo International files a counter lawsuit against R.J. Reynolds for patent infringement of No.US10555556B2.


In its lawsuit, Philip Morris International compared its product VUSE VIBE to the patent No.US10555556B2 and argued that VUSE VIBE falls within the protection scope of "claim 1". However, the lawsuit fails to provide a comparison of whether VUSE VIBE contains the "first and second capillary" related technical features. Even if the patent is not found to be "invalid", it may still not constitute infringement (interested readers can download and read the legal documents).


Previously, Philip Morris International launched a patent lawsuit against British American Tobacco in Germany using patent "EP2282649," which is similar to a capillary oil guide. The court ruled in favor of British American Tobacco, stating that there was no infringement, resulting in Philip Morris International losing the case.


What is the technology solution protected by Claim 1 of patent No.US10555556B2?


A cylinder (commonly known as an e-cigarette) used in an aerosol generation system comprises a liquid storage portion that includes a pod container to maintain the liquid aerosol formation matrix. The pod container has an opening and at least two fluidly connected components (oil guiding components) form the liquid storage portion. All e-liquids need a corresponding storage component.


The first component of the liquid storage section includes:


The first capillary material, including various oil-conducting materials, fiber such as cotton, porous materials like ceramics, is used to evenly distribute the heat generating element for the e-cigarette. It is located near the opening of the shell. The second capillary material comes into contact with the first material and is separated from the opening by the first material (and does not come into contact with the heating sheet). Additionally, the second component of the liquid storage portion includes:


This refers to a device that utilizes an aerosol-forming matrix (e-liquid) to maintain a liquid state and supply the resulting aerosol-forming matrix to a container (e-liquid reservoir) made of a second capillary material. The device includes a fluid-permeable heating element (e-liquid permeator) that extends over the opening of the shell and the average pore size or porosity of the first capillary material is smaller than that of the second capillary material.


The key issue addressed by this patent is:


By setting up two guiding capillaries, the e-liquid is evenly distributed and atomized in the heater, ensuring no waste or reductions in e-liquid due to a decrease in volume or change in angle. This guarantees a high-quality vaping experience with every puff.


2.2 Common oil leakage issues have been resolved. However, the corresponding Mesh products still suffer from oil leakage problems.


The key technology of this plan is:


The use of two different types of oil-conducting materials achieves an even distribution of e-liquid to the heating element according to the frequency of vaping, resulting in improved vaporization efficiency. Claim 1 is not limited to a specific structural form and various forms and materials of oil-conducting materials and heaters are given as examples, making the scope of the invention broad. The technical solution provided in the manual is worth studying and learning from, and perhaps even finding better improvements. To aid readers in analysis, the figures have been marked by the author.


Figure 1 shows the overall technical plan, taking reference from Mesh and IQOS VEEV e-cigarettes. The core principle of oil storage, oil delivery and atomization is presented in Figure 2. Figure 3 illustrates the axial flow of oil passing through the heater and being uniformly released as smoke through the porous ceramic. Figure 4 demonstrates the radial oil delivery system (similar to traditional cotton core + metal wire) for atomization.


Closing Remarks


The ongoing patent wars between two tobacco giants indicate that both HNB and electronic vaporizer companies may continue to face legal challenges. It is possible that tobacco corporations have not yet turned their attention to Chinese electronic cigarette manufacturers, possibly due to other priorities.


However, their weapons arsenal is indeed very extensive, their research and development speed is very fast, and they are constantly laying out new patents.


Attachment 1: Global Distribution of Patents in the Same Cluster


Attachment 2: Patent Texts from Various Countries


Attachment 3: US Patent and Trademark Office invalidity decision.


Statement:


1. This article is intended for internal research and communication within the industry. It does not provide any investment or brand recommendations. This article should not be used as the basis for any investments. 2. The data and analysis conclusions mentioned in this article have not been confirmed in writing with the companies involved. Therefore, all information should be verified with official company releases.


This article is an original creation of 2FIRSTS Technology Co. Ltd. in Shenzhen. The copyright and usage rights belong to the company and no individual or organization is allowed to use, reproduce or copy the content for commercial purposes without authorization. Any infringement of the company's copyright will be subject to legal action.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
IQOS Global Flagship Space to Open in Tokyo Ginza as PMI Expands Consumer Experience Strategy
IQOS Global Flagship Space to Open in Tokyo Ginza as PMI Expands Consumer Experience Strategy
Philip Morris Japan (PMJ) announced that it will open “IQOS Flagship Ginza” in Tokyo on September 4, 2026. The location will become the first global flagship space for PMI’s IQOS brand. PMJ said the venue will target adult smokers aged 20 and above and combine product experiences, community engagement and local cultural elements. The design will incorporate Japanese natural aesthetics and traditional craftsmanship. The launch reflects PMI’s broader strategy of strengthening consumer engagement through experiential retail and brand spaces. The existing IQOS Store Ginza is scheduled to close on August 30, 2026.
Jul.21
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
Product | SnowPlus Launches Nicotine-Free DASH in South Korea, Localising an Established Disposable Platform
SnowPlus has introduced a nicotine-free version of DASH in South Korea, adapting an existing overseas disposable platform for the local market. The Korean version retains the series’ flat duckbill-style mouthpiece, ceramic heating architecture and disposable form factor while reducing nicotine content to 0%. By comparison, the overseas DASH 4000 platform typically features 7.5ml of prefilled e-liquid, up to 4,000 puffs and a 530mAh rechargeable battery, with nicotine-containing variants available in some markets. The product update centers on formulation localisation rather than a new hardware generation.
Aug.31
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan Industrial Co., Ltd. has filed a patent application for a cellulose-free scaffold material for nicotine pouches, proposing a combination of bioceramic material, polydextrose and sugar alcohols to replace conventional microcrystalline cellulose and cellulose derivatives. The filing aims to address issues including powdery mouthfeel, residue and limited release control, while also reducing reliance on existing cellulose-based patent portfolios. In patent examples, one fast-release formulation reached a nicotine release rate of 50% at 10 minutes and more than 90% at 20 minutes.
Sep.02
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
Bret Koplow, acting director of the U.S. Food and Drug Administration's Center for Tobacco Products, will deliver a keynote and participate in a fireside chat at the National Association of Tobacco Outlets' Sept. 29-30 conference in Washington. His appearance comes months after the FDA moved to accelerate PMTA reviews and introduced a more differentiated enforcement policy for certain unauthorized ENDS and oral nicotine pouch products. The agency also plans a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement under the May guidance. NATO says its membership includes more than 66,000 retail stores, making product-status transparency and enforcement boundaries directly relevant to the retail sector.
Aug.14